Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance)

Purpose: We profiled circulating tumor cells (CTCs) to study the biology of blood-borne metastasis and to monitor biomarker status in metastatic breast cancer (MBC). Methods: CTCs were isolated from 105 patients with MBC using EPCAM-based immunomagnetic enrichment and fluorescence-activated cells sorting (IE/FACS), 28 of whom had serial CTC analysis (74 samples, 2–5 time points). CTCs were subjected to microfluidic-based multiplex QPCR array of 64 cancer-related genes (n = 151) and genome-wide copy-number analysis by array comparative genomic hybridization (aCGH; n = 49). Results: Combined transcriptional and genomic profiling showed that CTCs were 26% ESR1−ERBB2−, 48% ESR1+ERBB2−, and 27% ERBB2+. Serial testing showed that ERBB2 status was more stable over time compared with ESR1 and proliferation (MKI67) status. While cell-to-cell heterogeneity was observed at the single-cell level, with increasingly stable expression in larger pools, patient-specific CTC expression “fingerprints” were also observed. CTC copy-number profiles clustered into three groups based on the extent of genomic aberrations and the presence of large chromosomal imbalances. Comparative analysis showed discordance in ESR1/ER (27%) and ERBB2/HER2 (23%) status between CTCs and matched primary tumors. CTCs in 65% of the patients were considered to have low proliferation potential. Patients who harbored CTCs with high proliferation (MKI67) status had significantly reduced progression-free survival (P = 0.0011) and overall survival (P = 0.0095) compared with patients with low proliferative CTCs. Conclusions: We demonstrate an approach for complete isolation of EPCAM-positive CTCs and downstream comprehensive transcriptional/genomic characterization to examine the biology and assess breast cancer biomarkers in these cells over time. Clin Cancer Res; 24(6); 1486–99. ©2018 AACR.

[1]  Natali Gulbahce,et al.  Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. , 2017, Cancer research.

[2]  A. DeMichele,et al.  Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial , 2017 .

[3]  John W. Park,et al.  Circulating tumor cells in breast cancer: applications in personalized medicine , 2016, Breast Cancer Research and Treatment.

[4]  M. Ellis,et al.  Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Joel S. Parker,et al.  Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer , 2016, Bioinform..

[6]  C. Lindsay,et al.  Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer , 2016, BMC Cancer.

[7]  D. Hong,et al.  The isolation and characterization of CTC subsets related to breast cancer dormancy , 2015, Scientific Reports.

[8]  H. Rugo,et al.  Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer , 2015, Breast Cancer Research and Treatment.

[9]  Y. Asmann,et al.  The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831 , 2015, Breast Cancer Research.

[10]  E. Winer,et al.  Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Winer,et al.  TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Sleijfer,et al.  Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  T. Fehm,et al.  Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program , 2015, Archives of Gynecology and Obstetrics.

[14]  Minetta C. Liu,et al.  Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers , 2014, Clinical Cancer Research.

[15]  L. Ellis,et al.  Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression , 2014, Clinical Cancer Research.

[16]  Ben S. Wittner,et al.  Single-Cell RNA Sequencing Identifies Extracellular Matrix Gene Expression by Pancreatic Circulating Tumor Cells , 2014, Cell reports.

[17]  M. Davidson,et al.  The cancer glycocalyx mechanically primes integrin-mediated growth and survival , 2014, Nature.

[18]  John W. Park,et al.  Advances in genomic characterization of circulating tumor cells , 2014, Cancer and Metastasis Reviews.

[19]  Tanja Fehm,et al.  Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients , 2014, Journal of the National Cancer Institute.

[20]  T. Fehm,et al.  Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. , 2014, The Lancet. Oncology.

[21]  Caroline Dive,et al.  Molecular analysis of circulating tumour cells—biology and biomarkers , 2014, Nature Reviews Clinical Oncology.

[22]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[23]  A. González-Angulo,et al.  Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study , 2014, Breast Cancer Research and Treatment.

[24]  John W. Park,et al.  Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling. , 2013, Methods.

[25]  John W. Park,et al.  Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. , 2013, Cancer research.

[26]  I. Thompson,et al.  Single‐cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT‐related genes in metastatic prostate cancer , 2013, The Prostate.

[27]  Mehmet Toner,et al.  Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells , 2013, Science Translational Medicine.

[28]  Sridhar Ramaswamy,et al.  Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013, Science.

[29]  Adam Olshen,et al.  Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. , 2013, Cancer research.

[30]  M. Ronaghi,et al.  mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer , 2012, PloS one.

[31]  Joana Paredes,et al.  Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types , 2012, Journal of Clinical Pathology.

[32]  Rafael López-López,et al.  Molecular Characterization of Circulating Tumor Cells in Human Metastatic Colorectal Cancer , 2012, PloS one.

[33]  B. Ljung,et al.  Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[34]  J. Bergh,et al.  Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Sandberg,et al.  Full-Length mRNA-Seq from single cell levels of RNA and individual circulating tumor cells , 2012, Nature Biotechnology.

[36]  Sridhar Ramaswamy,et al.  RNA sequencing of pancreatic circulating tumour cells implicates WNT signaling in metastasis , 2012, Nature.

[37]  Gyan Bhanot,et al.  Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines , 2012, PloS one.

[38]  G. Barrière,et al.  Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis , 2012, BMC Cancer.

[39]  D. Pinkel,et al.  Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer , 2012, BMC Cancer.

[40]  Tanja Fehm,et al.  Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells , 2012, Breast Cancer Research.

[41]  M. Pfaffl,et al.  Quantification noise in single cell experiments , 2011, Nucleic acids research.

[42]  John W M Martens,et al.  mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients , 2011, Clinical Cancer Research.

[43]  L. Goldstein,et al.  Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M. Golightly,et al.  Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients , 2010, International journal of cancer.

[45]  Anne-Michelle Noone,et al.  Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Tanja Fehm,et al.  Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients , 2009, Breast Cancer Research.

[47]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  John A. Foekens,et al.  Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR , 2009, Breast Cancer Research and Treatment.

[49]  Martin Hemberg,et al.  Quantification of mRNA in single cells and modelling of RT-qPCR induced noise , 2008, BMC Molecular Biology.

[50]  Ajay N. Jain,et al.  Breast tumor copy number aberration phenotypes and genomic instability , 2006, BMC Cancer.

[51]  P. Carroll,et al.  Bladder cancer stage and outcome by array-based comparative genomic hybridization. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  Thomas Ragg,et al.  The RIN: an RNA integrity number for assigning integrity values to RNA measurements , 2006, BMC Molecular Biology.

[53]  K. Pienta,et al.  Global gene expression profiling of circulating tumor cells. , 2005, Cancer research.

[54]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[55]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[56]  L. Terstappen,et al.  Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. , 2004, Clinical chemistry.

[57]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[58]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[59]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[60]  R. Fisher.  FREQUENCY DISTRIBUTION OF THE VALUES OF THE CORRELATION COEFFIENTS IN SAMPLES FROM AN INDEFINITELY LARGE POPU;ATION , 1915 .

[61]  K. Pearson.  VII. Note on regression and inheritance in the case of two parents , 1895, Proceedings of the Royal Society of London.